The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... 2-venture-oral-dosing-trial-of-vk2735-tablet-formulation-in-patients-with ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

Viking is currently conducting the Phase 2 VENTURE-Oral Dosing Trial of VK2735 dosed as an oral tablet once daily for ... of internally developed dual amylin and calcitonin receptor agonists ...

This trend has been carried on to their tablets, which don’t get as much spotlight as they should. The rave about tablets has died down in recent years, but there are unique additions in this ...

If you’re on the hunt for the ultimate portable gaming machine in 2025, tablets are no longer just large-screen companions for streaming and browsing — they’ve become powerful gaming devices ...

I've tested many tablets, but few have made such a huge difference as the TCL Nxtpaper technology. So I was glad to learn that a new version of one of my favorite tablets, the TCL Nxtpaper 11 Plus ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.